Experimental triple therapy takes on tough tumors
NCT ID NCT06760481
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This early-phase trial is testing a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus a special type of radiation (RadScopal) in 7 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects. Researchers hope this mix might help the immune system fight cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tiragolumab, Atezolizumab, and RadScopal radiation
What this could lead to
If it works, this could point toward a new combination therapy for advanced cancers that have run out of standard options.
What could go wrong
This is a very early Phase I trial with only 7 participants, so it is primarily testing safety, not effectiveness. The combination may cause significant side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.